Business

Australian CSL under exclusive negotiations to acquire Swiss Vifor Pharma

© Reuters. File photo: On June 15, 2017, the company logo is drawn on the CSL Behring building in Bern, Switzerland. REUTERS / Denis Balibouse

(Reuters)-Australia’s biotechnology giant CSL Ltd is in exclusive talks to buy Vifor Pharma for an A $ 10 billion ($ 7.1 billion) deal, Australia reported Thursday. It exceeded the stock by more than 17%.

The newspaper reported in March that CSL’s acquisition of Vifor may be underway. Negotiations have been underway since then, according to the latest report.

Vifor Pharma and CSL said in separate statements that they would not comment on speculation.

At the top of the Swiss midcap index, Vifor’s share price rose 21% and Thursday’s CSL fell 1.3%.

($ 1 = 1.4083 Australian dollars)

Disclaimer: Fusion media We inform you that the data contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are provided by the market maker, not the exchange, so prices may not be accurate and may differ from actual market prices. In other words, price is an indicator and is not suitable for trading purposes. Therefore, Fusion Media is not responsible for any transactional losses that may occur as a result of using this data.

Fusion media Alternatively, anyone involved in Fusion Media will not be liable for any loss or damage resulting from reliance on the data, quotes, charts, trading signals and other information contained on this website. Be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.

Australian CSL under exclusive negotiations to acquire Swiss Vifor Pharma

Source link Australian CSL under exclusive negotiations to acquire Swiss Vifor Pharma

Related Articles

Back to top button